Top

Published in:

01-04-2018

Prognostic factors of regrowth in nonfunctioning pituitary tumors

Authors: Gerald Raverot, Alexandre Vasiljevic, Emmanuel Jouanneau

Published in: Pituitary | Issue 2/2018

Abstract

Surgery is the treatment of choice for nonfunctioning pituitary tumors (NFPTs). Postoperative tumor regrowth during follow-up is present in about half of the patients with invasive NFPTs with residual tumor but occurs also in 15% of patient without residue. Therapeutic strategies should consider this risk of recurrence and the potential side effects associated with therapeutic options. Identification of prognostic markers is mandatory to help clinicians to predict the risk of recurrence and to choose the best strategy between conservative follow-up, second surgery, postoperative adjuvant radiation therapy, and medical treatment (dopamine agonists, somatostatin analogs). Recent advances in pathological classification may be the first step for identification of NFPTs with a high risk of recurrence.

Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, Korbonits M, Laws ER Jr, Lopes MB, Maartens N, McCutcheon IE, Mete O, Nishioka H, Raverot G, Roncaroli F, Saeger W, Syro LV, Vasiljevic A, Villa C, Wierinckx A, Trouillas J, and the attendees of 14th Meeting of the International Pituitary Pathology Club, A.F.N. (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer 24(4):C5–C8. https://doi.org/10.1530/ERC-17-0004 CrossRefPubMed

Vasiljevic A, Jouanneau E, Trouillas J, Raverot G (2016) Clinicopathological prognostic and theranostic markers in pituitary tumors. Minerva Endocrinol 41(3):377–389PubMed

Gittoes NJ, Bates AS, Tse W, Bullivant B, Sheppard MC, Clayton RN, Stewart PM (1998) Radiotherapy for non-function pituitary tumours. Clin Endocrinol 48(3):331–337CrossRef

Greenman Y, Ouaknine G, Veshchev I, Reider G II, Segev Y, Stern N (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol 58(6):763–769CrossRef

Tampourlou M, Ntali G, Ahmed S, Arlt W, Ayuk J, Byrne JV, Chavda S, Cudlip S, Gittoes N, Grossman A, Mitchell R, O’Reilly MW, Paluzzi A, Toogood A, Wass JA, Karavitaki N (2017) Outcome of non-functioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2016-4061 PubMed

Ayuk J, Stewart PM (2009) Mortality following pituitary radiotherapy. Pituitary 12(1):35–39. https://doi.org/10.1007/s11102-007-0083-1 CrossRefPubMed

Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B (2002) Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol 57(6):713–717CrossRef

Erfurth EM, Bulow B, Svahn-Tapper G, Norrving B, Odh K, Mikoczy Z, Bjork J, Hagmar L (2002) Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 87(11):4892–4899. https://doi.org/10.1210/jc.2002-020526 CrossRefPubMed

Hahn CA, Zhou SM, Raynor R, Tisch A, Light K, Shafman T, Wong T, Kirkpatrick J, Turkington T, Hollis D, Marks LB (2009) Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. Int J Radiat Oncol Biol Phys 73(4):1082–1087. https://doi.org/10.1016/j.ijrobp.2008.05.061 CrossRefPubMed

10.

Burman P, van Beek AP, Biller BM, Camacho-Hübner C, Mattsson AF (2017) Radiotherapy, especially at young age, increases the risk for de novo brain tumors in patients treated for pituitary/sellar lesions. J Clin Endocrinol Metab 102(3):1051–1058. https://doi.org/10.1210/jc.2016-3402 PubMed

11.

Greenman Y (2017) Management of endocrine disease: present and future perspectives for medical therapy of nonfunctioning pituitary adenomas. Eur J Endocrinol 177(3):R113–R124. https://doi.org/10.1530/EJE-17-0216 CrossRefPubMed

12.

Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1):71–83. https://doi.org/10.1007/s11102-011-0347-7 CrossRefPubMed

13.

Cortet-Rudelli C, Bonneville JF, Borson-Chazot F, Clavier L, Coche Dequéant B, Desailloud R, Maiter D, Rohmer V, Sadoul JL, Sonnet E, Toussaint P, Chanson P (2015) Post-surgical management of non-functioning pituitary adenoma. Ann Endocrinol 76(3):228–238. https://doi.org/10.1016/j.ando.2015.04.003 CrossRef

14.

Kremer P, Forsting M, Ranaei G, Wuster C, Hamer J, Sartor K, Kunze S (2002) Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochir 144(5):433–443. https://doi.org/10.1007/s007010200064 CrossRefPubMed

15.

Chen Y, Wang CD, Su ZP, Chen YX, Cai L, Zhuge QC, Wu ZB (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4):333–342. https://doi.org/10.1159/000339823 CrossRefPubMed

16.

Reddy R, Cudlip S, Byrne JV, Karavitaki N, Wass JA (2011) Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur J Endocrinol 165(5):739–744. https://doi.org/10.1530/EJE-11-0566 CrossRefPubMed

17.

Brochier S, Galland F, Kujas M, Parker F, Gaillard S, Raftopoulos C, Young J, Alexopoulou O, Maiter D, Chanson P (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 163(2):193–200. https://doi.org/10.1530/EJE-10-0255EJE-10-0255 CrossRefPubMed

18.

Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102(9):3368–3374. https://doi.org/10.1210/jc.2017-00773 CrossRefPubMed

19.

Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, François P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G, Barlier A, Bernier M, Bonnet F, Borson-Chazot F, Brassier G, Caulet-Maugendre S, Chabre O, Chanson P, Cottier JF, Delemer B, Delgrange E, Di Tommaso L, Eimer S, Gaillard S, Jan M, Girard JJ, Lapras V, Loiseau H, Passagia JG, Patey M, Penfornis A, Poirier JY, Perrin G, Tabarin A (2013) HYPOPRONOS, m.o.: a new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135. https://doi.org/10.1007/s00401-013-1084-y CrossRefPubMed

20.

Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108(3):525–532. https://doi.org/10.3171/JNS/2008/108/3/0525 CrossRefPubMed

21.

Micko AS, Wöhrer A, Wolfsberger S, Knosp E (2015) Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg 122(4):803–811. https://doi.org/10.3171/2014.12.JNS141083 CrossRefPubMed

22.

Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610–617 (discussion 617–618)CrossRefPubMed

23.

Saeger W, Petersenn S, Schöfl C, Knappe UJ, Theodoropoulou M, Buslei R, Honegger J (2016) Emerging histopathological and genetic parameters of pituitary adenomas: clinical impact and recommendation for future WHO classification. Endocr Pathol 27(2):115–122. https://doi.org/10.1007/s12022-016-9419-6 CrossRefPubMed

24.

Galland F, Lacroix L, Saulnier P, Dessen P, Meduri G, Bernier M, Gaillard S, Guibourdenche J, Fournier T, Evain-Brion D, Bidart JM, Chanson P (2010) Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 17(2):361–371. https://doi.org/10.1677/ERC-10-0018ERC-10-0018 CrossRefPubMed

25.

Yu SY, Hong LC, Feng J, Wu YT, Zhang YZ (2016) Integrative proteomics and transcriptomics identify novel invasive-related biomarkers of non-functioning pituitary adenomas. Tumour Biol 37(7):8923–8930. https://doi.org/10.1007/s13277-015-4767-2 CrossRefPubMed

26.

Øystese KA, Evang JA, Bollerslev J (2016) Non-functioning pituitary adenomas: growth and aggressiveness. Endocrine 53(1):28–34. https://doi.org/10.1007/s12020-016-0940-7 CrossRefPubMed

27.

Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98(2):359–365. https://doi.org/10.3171/jns.2003.98.2.0359 CrossRefPubMed

28.

Monsalves E, Larjani S, Godoy LB, Juraschka K, Carvalho F, Kucharczyk W, Kulkarni A, Mete O, Gentili F, Ezzat S, Zadeh G (2014) Growth patterns of pituitary adenomas and histopathological correlates. J Clin Endocrinol Metab 99(4):1330–1338. https://doi.org/10.1210/jc.2013-3054 CrossRefPubMed

29.

Chanson P, Raverot G, Castinetti F, Cortet-Rudelli C, Galland F, Salenave S (2015) Management of clinically non-functioning pituitary adenoma. Ann Endocrinol 76(3), 239–247. https://doi.org/10.1016/j.ando.2015.04.002 CrossRef

30.

Oystese KA, Casar-Borota O, Normann KR, Zucknick M, Berg JP, Bollerslev J (2017) Estrogen receptor alpha, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA. J Clin Endocrinol Metab 102(9):3581–3590. https://doi.org/10.1210/jc.2017-00792 CrossRefPubMed

31.

Bradley KJ, Wass JA, Turner HE (2003) Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol 58(1):59–64CrossRef

32.

Cooper O (2015) Silent corticotroph adenomas. Pituitary 18(2):225–231. https://doi.org/10.1007/s11102-014-0624-3 CrossRefPubMedPubMedCentral

33.

Langlois F, Lim DST, Varlamov E, Yedinak CG, Cetas JS, McCartney S, Dogan A, Fleseriu M (2017) Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience. Endocrine. https://doi.org/10.1007/s12020-017-1447-6 PubMed

34.

Chinezu L, Vasiljevic A, Trouillas J, Lapoirie M, Jouanneau E, Raverot G (2017) Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol 176(2):195–201. https://doi.org/10.1530/EJE-16-0738 CrossRefPubMed

35.

Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J, Raverot G (2012) New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15(1):37–43. https://doi.org/10.1007/s11102-011-0341-0 CrossRefPubMed

36.

Baldeweg SE, Pollock JR, Powell M, Ahlquist J (2005) A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg 19(1):38–42. https://doi.org/10.1080/02688690500081230 CrossRefPubMed

37.

Langlois F, Lim DST, Yedinak CG, Cetas I, McCartney S, Cetas J, Dogan A, Fleseriu M (2017) Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary. https://doi.org/10.1007/s11102-017-0844-4

38.

Raverot G, Burman P, McCormack AI, Heaney AP, Petersenn S, Popovic V, Trouillas J, Dekkers O (2017) European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. https://doi.org/10.1530/EJE-17-0796

39.

DeLellis RA (2004) Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon

40.

De Caro MD, Solari D, Pagliuca F, Villa A, Guadagno E, Cavallo LM, Colao A, Pettinato G, Cappabianca P (2016) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev. https://doi.org/10.1007/s10143-016-0740-9

41.

Yildirim AE, Divanlioglu D, Nacar OA, Dursun E, Sahinoglu M, Unal T, Belen AD (2013) Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas. Turk Neurosurg 23(2):226–231. https://doi.org/10.5137/1019-5149.JTN.6828-12.1 PubMed

42.

Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59(2):341–353 (discussion 341–353)CrossRefPubMed

43.

Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114(2):336–344. https://doi.org/10.3171/2010.8.JNS10290 CrossRefPubMed

44.

Saeger W, Lüdecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the germain pituitary tumors registry. Eur J Endocrinol 156:203–216CrossRefPubMed

45.

Chiloiro S, Doglietto F, Trapasso B, Iacovazzo D, Giampietro A, Di Nardo F, de Waure C, Lauriola L, Mangiola A, Anile C, Maira G, De Marinis L, Bianchi A (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101(2):143–150. https://doi.org/10.1159/000375448 CrossRefPubMed

46.

Lloyd RV, Osamura RY, Klöppel G, Rosai J (2017) Pathology and genetics of tumours of endocrine organs. World Health Organization classification of tumours, vol 4th. IARC press, Lyon

47.

Kovacs K, Rotondo F, Horvath E, Syro LV, Di Ieva A, Cusimano MD, Munoz DG (2015) Letter to the editor. Endocr Pathol 26(1):93–94. https://doi.org/10.1007/s12022-014-9342-7 CrossRefPubMed

48.

Ezzat S, Zheng L, Asa SL (2004) Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: a mechanism underlying pituitary neoplasia. Mol Endocrinol 18(10):2543–2552. https://doi.org/10.1210/me.2004-0182me.2004-0182 CrossRefPubMed

49.

Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. https://doi.org/10.1111/j.1750-3639.2012.00578.x PubMed

50.

Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J (2010) Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol 326(1–2):30–39. https://doi.org/10.1016/j.mce.2010.02.043 CrossRefPubMed

51.

Wierinckx A, Roche M, Legras-Lachuer C, Trouillas J, Raverot G, Lachuer J (2017) MicroRNAs in pituitary tumors. Mol Cell Endocrinol 456:51–61. https://doi.org/10.1016/j.mce.2017.01.021 CrossRefPubMed

52.

Marko NF, Coughlan C, Weil RJ (2012) Towards an integrated molecular and clinical strategy to predict early recurrence in surgically resected non-functional pituitary adenomas. J Clin Neurosci 19(11):1535–1540. https://doi.org/10.1016/j.jocn.2012.01.038S0967-5868(12)00237-8 CrossRefPubMed

53.

Bi WL, Horowtiz P, Greenwald N, Abedalthagafi M, Agarwalla PK, Gibson WJ, Mei Y, Schumacher SE, Ben-David U, Chevalier A, Carter SL, Tiao G, Brastianos PK, Ligon AH, Ducar M, MacConaill LE, Laws ER, Santagata S, Beroukhim R, Dunn IF (2016) Landscape of genomic alterations in pituitary adenomas. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-16-0790 PubMedPubMedCentral

54.

Feng J, Hong L, Wu Y, Li C, Wan H, Li G, Sun Y, Yu S, Chittiboina P, Montgomery B, Zhuang Z, Zhang Y (2014) Identification of a subtype-specific ENC1 gene related to invasiveness in human pituitary null cell adenoma and oncocytomas. J Neurooncol 119(2):307–315. https://doi.org/10.1007/s11060-014-1479-1 CrossRefPubMedPubMedCentral

55.

Matano F, Yoshida D, Ishii Y, Tahara S, Teramoto A, Morita A (2014) Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J Neurooncol 117(3):485–491. https://doi.org/10.1007/s11060-014-1377-6 CrossRefPubMed

56.

Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G, Trouillas J (2015) Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. Eur J Endocrinol 172(6):791–801. https://doi.org/10.1530/EJE-14-0990 CrossRefPubMed

57.

Bi WL, Greenwald NF, Ramkissoon SH, Abedalthagafi M, Coy SM, Ligon KL, Mei Y, MacConaill L, Ducar M, Min L, Santagata S, Kaiser UB, Beroukhim R, Laws ER Jr, Dunn IF (2017) Clinical Identification of oncogenic drivers and copy-number alterations in pituitary tumors. Endocrinology 158(7):2284–2291. https://doi.org/10.1210/en.2016-1967 CrossRefPubMed

Title: Prognostic factors of regrowth in nonfunctioning pituitary tumors
Authors: Gerald Raverot
Alexandre Vasiljevic
Emmanuel Jouanneau
Publication date: 01-04-2018
Publisher: Springer US
Published in: Pituitary / Issue 2/2018
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-017-0861-3

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Non-functioning pituitary adenomas, not all the same and certainly not boring!

How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review

Silent somatotroph pituitary adenomas: an update

Management of nonfunctioning pituitary tumors: radiotherapy

Silent corticotroph adenomas

Management of non-functioning pituitary adenomas: surgery

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage